Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 20;9:871541. doi: 10.3389/fmolb.2022.871541

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Baghani, Noroozi Heris, Khonsari, Dinarvand, Dinarvand and Atyabi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Therapeutic effects of AuNPs-TMC/siRNA. (A) Cell viability percentage of MCF-7 cells after 48 h incubation with AuNPs-TMC, Free siRNA and AuNPs-TMC/siRNA (w/w ratio 10:1) at different concentration of NPs (28, 56 and 112 μg/ml) and siRNA (50, 100 and 200 nM). Data is shown as mean ± SD (N = 3). Statistical analysis: Two-way ANOVA, post-test Sidak, (***p < 0.001 significantly difference between columns). (B) Relative gene expression percent of EGFR in MCF-7 cells after 24 h incubation with AuNPs-TMC/EGFR-siRNA in w/w ratio of 10:1 (56 μg/ml/100 nM) using RT-PCR method. (KD = knockdown). (C) Apoptosis assay in MCF-7 cancer cells following no treatment and treatment with AuNPs-TMC, Free siRNA and AuNPs-TMC/EGFR-siRNA (56 μg/ml/100 nM) after 24 h using annexin V-FITC/PI staining.